Improved Markers of Cholestatic Liver Injury in Patients With Primary Biliary Cholangitis Treated With Obeticholic Acid and Bezafibrate
Lena Smets, Jef Verbeek, Hannelie Korf, Schalk Merwe, Frederik Nevens – 3 November 2020
Erratum
3 November 2020
Thromboelastography and Utility in Hepatology Practice
Abhishek Shenoy, Nicolas M. Intagliata – 3 November 2020
Portal and Mesenteric Venous Thrombosis
Sudha Kodali, Ashwani K. Singal – 3 November 2020
Assessment of Noninvasive Markers of Liver Fibrosis in Patients With Chronic Hepatitis C in Ethiopia
Hailemichael Desalegn, Yemisrach Chanie, Paulos Shume, Miftah Delil, Neil Gupta, Asgeir Johannessen – 3 November 2020
Association of Metabolic Risk Factors With Risks of Cancer and All‐Cause Mortality in Patients With Chronic Hepatitis B
Yun Bin Lee, Hyemi Moon, Jeong‐Hoon Lee, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Fabien Zoulim, Juneyoung Lee, Jung‐Hwan Yoon – 2 November 2020
Associations Between Intake of Sugar‐Containing Beverages in Infancy With Liver Fat Accumulation at School Age
Madelon L. Geurtsen, Susana Santos, Romy Gaillard, Janine F. Felix, Vincent W. V. Jaddoe – 2 November 2020
Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin‐Like Phospholipase Domain Containing 3–Mediated Acceleration of Steatohepatitis
Bubu A. Banini, Divya P. Kumar, Sophie Cazanave, Mulugeta Seneshaw, Faridoddin Mirshahi, Prasanna K. Santhekadur, Liangsu Wang, Hong Ping Guan, Abdul M. Oseini, Cristina Alonso, Pierre Bedossa, Srinivas V. Koduru, Hae‐Ki Min, Arun J. Sanyal – 1 November 2020
Comparison of Long‐Term Clinical Outcomes Between Spontaneous and Therapy‐Induced HBsAg Seroclearance
Jonggi Choi, Sun Yoo, Young‐Suk Lim – 1 November 2020
Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting
Joana Vieira Barbosa, Michelle Lai – 31 October 2020 – Nonalcoholic fatty liver disease (NAFLD) is a major public health problem worldwide and the most common chronic liver disease. NAFLD currently affects approximately one in every four people in the United States, and its global burden is expected to rise in the next decades. Despite being a prevalent disease in the general population, only a minority of patients with NAFLD will develop nonalcoholic steatohepatitis (NASH) with advanced liver fibrosis (stage 3‐4 fibrosis) and liver‐related complications.